FDA Approves IDE study assessing Revita for weight maintenance after discontinuation of GLP-1The FDA has approved a pivotal Investigational Device Exemption (IDE) to study the efficacy of Fractyl Health’s Revita system for...
GLP-1s associated with higher risk of major depression, increased risk for anxiety and an elevated risk for suicidal behaviour1 day ago